Salix Pharmaceuticals announced Thursday that the U.S. Food and Drug Administration has approved the Raleigh company’s drug Ruconest for treatment of acute angioedema attacks.
Angioedema is a swelling just under the skin that is similar to hives.
Salix developed the drug with the Dutch drugmaker Pharming Group NV.
Ruconest was one of the drugs being developed by the specialty drug company Santarus, which Salix acquired for $2.6 billion earlier this year.
In an analyst presentation earlier this month, Salix executives estimated that Ruconest could have peak annual sales of $87 million for treatment of acute hereditary angioedema. The company said the drug could be worth much more if it is approved to prevent angioedema attacks.
Salix shares were down 92 cents at $131.99 in mid-day trading Thursday.